Drug Development

Sep 27, 2017
The authors review R&D trends in the pharmaceutical industry, particularly the advancement in biologics drug development.
Sep 19, 2017
By Pharmaceutical Technology Editors
The collaboration with Immunocore, a T cell receptor company, aims to discover and develop immunotherapy molecules to treat infectious diseases.
Sep 19, 2017
By identifying patterns, artificial intelligence and deep learning platforms help researchers discover new drugs faster.
Sep 14, 2017
By Pharmaceutical Technology Editors
Kancera’s drug candidate KAND567 will be developed as a capsule formulation for oral administration. Work will be performed at Recipharm’s development facility in Solna, Sweden.
Sep 12, 2017
By Pharmaceutical Technology Editors
Bayer will use Berkeley Lights’ platform of nanofluidic chips that automate biological workflows, including cell-line development and antibody discovery and engineering.
Sep 11, 2017
By Pharmaceutical Technology Editors
BARDA has awarded Summit, a drug discovery and development company, a contract worth up to $62 million over five years for the development of a new small-molecule antibiotic.
Sep 08, 2017
By Pharmaceutical Technology Editors
Scientists at Scripps’ Florida campus showed for the first time that quality control steps exist in the production of proteins, which presents a target for anti-cancer drug development.
Sep 01, 2017
Pharmaceutical Technology
Pulmonary drug delivery is becoming increasingly used. When developing pulmonary drugs, pharmaceutical chemists must consider drug absorption, control of particle size, suitable toxicology models, and patient compliance. The author reviews the issues specific to developing drugs designed for pulmonary delivery and considers how—with the right knowledge and expertise—these challenges can be overcome.
Aug 31, 2017
By Pharmaceutical Technology Editors
MilliporeSigma announced a collaboration with Angiex, a biotechnology start-up, to support the development of Angiex’s lead oncology antibody drug candidate to clinical use.
Aug 29, 2017
By Pharmaceutical Technology Editors
AstraZeneca and Takeda will partner to develop and commercialize MEDI1341, an alpha-synuclein antibody currently in development as a potential treatment for Parkinson’s disease (PD).
lorem ipsum